Skip to main content

Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Publication ,  Journal Article
Preusser, M; Lim, M; Hafler, DA; Reardon, DA; Sampson, JH
Published in: Nat Rev Neurol
September 2015

Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even with the current gold-standard first-line treatment—maximal safe resection and combination of radiotherapy with temozolomide chemotherapy—the median overall survival time is only approximately 15-17 months, because the tumour recurs in virtually all patients, and no commonly accepted standard treatment for recurrent disease exists. Several targeted agents have failed to improve patient outcomes in glioblastoma. Immunotherapy with immune checkpoint inhibitors such as ipilimumab, nivolumab, and pembrolizumab has provided relevant clinical improvements in other advanced tumours for which conventional therapies have had limited success, making immunotherapy an appealing strategy in glioblastoma. This Review summarizes current knowledge on immune checkpoint modulators and evaluates their potential role in glioblastoma on the basis of preclinical studies and emerging clinical data. Furthermore, we discuss challenges that need to be considered in the clinical development of drugs that target immune checkpoint pathways in glioblastoma, such as specific properties of the immune system in the CNS, issues with radiological response assessment, and potential interactions with established and emerging treatment strategies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

September 2015

Volume

11

Issue

9

Start / End Page

504 / 514

Location

England

Related Subject Headings

  • Immunotherapy
  • Immunologic Factors
  • Humans
  • Glioblastoma
  • Clinical Trials as Topic
  • Brain Neoplasms
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015). Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol, 11(9), 504–514. https://doi.org/10.1038/nrneurol.2015.139
Preusser, Matthias, Michael Lim, David A. Hafler, David A. Reardon, and John H. Sampson. “Prospects of immune checkpoint modulators in the treatment of glioblastoma.Nat Rev Neurol 11, no. 9 (September 2015): 504–14. https://doi.org/10.1038/nrneurol.2015.139.
Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015 Sep;11(9):504–14.
Preusser, Matthias, et al. “Prospects of immune checkpoint modulators in the treatment of glioblastoma.Nat Rev Neurol, vol. 11, no. 9, Sept. 2015, pp. 504–14. Pubmed, doi:10.1038/nrneurol.2015.139.
Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015 Sep;11(9):504–514.

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

September 2015

Volume

11

Issue

9

Start / End Page

504 / 514

Location

England

Related Subject Headings

  • Immunotherapy
  • Immunologic Factors
  • Humans
  • Glioblastoma
  • Clinical Trials as Topic
  • Brain Neoplasms
  • Animals